Soluble siglec5: A new prognosis marker in colorectal cancer patients

8Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Colorectal cancer (CRC) is the second most deadly and third most commonly diagnosed cancer worldwide. There is significant heterogeneity among patients with CRC, which hinders the search for a standard approach for the detection of this disease. Therefore, the identification of ro-bust prognostic markers for patients with CRC represents an urgent clinical need. In search of such biomarkers, a total of 114 patients with colorectal cancer and 67 healthy participants were studied. Soluble SIGLEC5 (sSIGLEC5) levels were higher in plasma from patients with CRC compared with healthy volunteers. Additionally, sSIGLEC5 levels were higher in exitus than in survivors, and the receiver operating characteristic curve analysis revealed sSIGLEC5 to be an exitus predictor (area under the curve 0.853; cut‐off > 412.6 ng/mL) in these patients. A Kaplan–Meier analysis showed that patients with high levels of sSIGLEC5 had significantly shorter overall survival (hazard ratio 15.68; 95% CI 4.571–53.81; p ≤ 0.0001) than those with lower sSIGLEC5 levels. Our study suggests that sSIGLEC5 is a soluble prognosis marker and exitus predictor in CRC.

Cite

CITATION STYLE

APA

Montalbán‐hernández, K., Cantero‐cid, R., Lozano‐rodríguez, R., Pascual‐iglesias, A., Avendaño‐ortiz, J., Casalvilla‐dueñas, J. C., … Collazo, E. L. (2021). Soluble siglec5: A new prognosis marker in colorectal cancer patients. Cancers, 13(15). https://doi.org/10.3390/cancers13153896

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free